Edition:
India

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

43.01USD
10:27pm IST
Change (% chg)

$0.66 (+1.56%)
Prev Close
$42.35
Open
$42.29
Day's High
$43.27
Day's Low
$41.58
Volume
30,203
Avg. Vol
146,501
52-wk High
$46.51
52-wk Low
$23.07

Latest Key Developments (Source: Significant Developments)

Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Acceleron Pharma Inc ::ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018.ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH FACIOSCAPULOHUMERAL DYSTROPHY.  Full Article

Acceleron Pharma qtrly net loss per share $0.65
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Acceleron Pharma Inc :Acceleron Pharma reports third quarter 2017 operational and financial results.Acceleron Pharma Inc - ‍existing cash, cash equivalents and investments will be sufficient to fund projected operating requirements into 2021​.Acceleron Pharma Inc qtrly net loss per share applicable to common stockholders basic and diluted $0.65.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

Acceleron:Habib Dable named president and ceo
Wednesday, 28 Sep 2016 

Acceleron Pharma Inc : Acceleron announces retirement of John Knopf as president and ceo; Habib Dable named as successor . Habib Dable appointed as president and ceo .Acceleron Pharma Inc says Habib Dable will assume ceo role effective December 1, 2016.  Full Article

Acceleron Pharma Q2 loss per share $0.59
Thursday, 4 Aug 2016 

Acceleron Pharma Inc : Acceleron Pharma reports second quarter 2016 financial and operational results . Q2 loss per share $0.59 .Q2 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Acceleron announces ACE-083 phase 1 results
Friday, 8 Jul 2016 

Acceleron Pharma Inc : Announces ACE-083 phase 1 results at 14th International Congress On Neuromuscular Diseases . ACE-083 increased muscle volume of tibialis anterior muscle by 8.9% in healthy volunteers .Acceleron intends to advance ACE-083 into a phase 2 clinical trial in patients with FSHD in second half of 2016..  Full Article

Acceleron, Celgene says data with Luspatercept show increases in hemoglobin levels
Friday, 10 Jun 2016 

Acceleron Pharma Inc : Acceleron and Celgene announce updated results from an ongoing Phase 2 study of Luspatercept in beta-thalassemia presented at the 21st congress of the European Hematology Association . Longer term data with investigational drug Luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden . Results showed 51% of patients with lower risk MDS treated with Luspatercept (n=49) achieved increased hemoglobin levels .Results showed 36% of patients achieved a hemoglobin increase of at least 1.5 g/dl in Luspatercept 3-month base study.  Full Article

BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018

* ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018